Development of tandem canine CAR T cells to enable comparative studies of aggressive B-cell lymphoma

Molecular Cancer Therapeutics · Published 2026-07-21 · DOI 10.1158/1535-7163.mct-26-0365

Free full text

Authors (7)

Brandon Peng, Lang Jiang, Jennifer A. Lenz, Luiza Cesar Conti, Antonia Rotolo, Nicola J. Mason, Matthew J. Atherton

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Peng, B., Jiang, L., Lenz, J., et al. (2026). Development of tandem canine CAR T cells to enable comparative studies of aggressive B-cell lymphoma. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-26-0365

Related articles

• Selected Articles from This Issue · Molecular Cancer Therapeutics · 2026 · Same journal
• RIG-I-targeted immunotherapy synergizes with immune checkpoint inhibition in a hepatocellular carcinoma model · Molecular Cancer Therapeutics · 2026 · Same journal
• HDAC Inhibition Unlocks Tumor Plasticity and Enhances Immunotherapy Response in Myc-Driven Small Cell Lung Cancer · Molecular Cancer Therapeutics · 2026 · Same journal
• Selected Articles from This Issue · Molecular Cancer Therapeutics · 2026 · Same journal
• Targeting NDUFS4 Disrupts Oxidative Phosphorylation and Induces Ferroptosis in Olaparib-Resistant Prostate Cancer · Molecular Cancer Therapeutics · 2026 · Same journal
• Mutant-Selective T-cell Receptor Therapy for Solid Tumors · Molecular Cancer Therapeutics · 2026 · Same journal
• Tinengotinib (TT-00420) inhibits tumor growth and overcomes multidrug resistance in gastrointestinal cancers · Molecular Cancer Therapeutics · 2026 · Same journal
• PRMT5 Inhibition by SCR-6920 Downregulates HIF-1α and Exhibits Synergistic Antitumor Activity with Bevacizumab in Ovarian Cancer · Molecular Cancer Therapeutics · 2026 · Same journal
• Fedratinib Induces Nonclassical G2–M Arrest via Mitotic Kinase Inhibition and Synergizes with Mitomycin C to Suppress Pancreatic Ductal Adenocarcinoma · Molecular Cancer Therapeutics · 2026 · Same journal
• Tri-Specific Humabody CB307 Targeting CD137, Prostate-Specific Membrane Antigen, and Human Serum Albumin Whole-Body Biodistribution Measured with 89Zr-CB307 PET · Molecular Cancer Therapeutics · 2026 · Same journal